Russia has developed a cancer vaccine, with plans to distribute it free of charge to patients pending regulatory approval. The vaccine has shown 100% efficacy and safety in clinical trials and uses AI-driven algorithms to create individualized mRNA blueprints based on patient genetic data. Clinical trials are underway, targeting over 300 cancer types, including colorectal, glioblastoma, and melanoma. The vaccine could be available for clinical use as early as September or October 2025, following regulatory approval.
